Monthly Archives: August 2022

Phosphoproteomics contribution published in Nature revealing that truncated FGFR2 leads to hyperactivity and is a clinically actionable oncogene

  • August 14, 2022
  • Comments off

Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical responses to available therapies remained variable and unpredictable, making it difficult to select patients who would benefit from these types of treatments. An international team of researchers led by Jos Jonkers, group leader at the […]

Read More